Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

Oracle Corporation

organization80% conf.·synced Oct 15, 2026

Technology company that adopted Custom AI Companion for global workforce AI assistants

60
sourced metrics
779
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
313.00USD
Oct 14, 2026reference only
Stock Price
130.55USD
Oct 14, 2026reference only
Price 52 Week Low
114.99USD
Oct 14, 2026reference only
Market Cap
376045489050USD
Oct 14, 2026reference only
Stock Return Ytd
-33.3%
Oct 14, 2026reference only
Shares Outstanding
2880471000.0shares
Jun 12, 2026reference only
Cash
31289000000.0USD
May 31, 2026reference only
Total Assets
261759000000.0USD
May 31, 2026reference only
Revenue
67357000000.0USD
May 31, 2026reference only
Operating Cash Flow
31977000000.0USD
May 31, 2026reference only
Capex
55663000000.0USD
May 31, 2026reference only
Stockholders Equity
42508000000.0USD
May 31, 2026reference only
Net Income
17087000000.0USD
May 31, 2026reference only
Eps
5.83USD_per_share
May 31, 2026reference only
Rd Expense
10272000000.0USD
May 31, 2026reference only
Operating Income
20606000000.0USD
May 31, 2026reference only

Stated objectives

Oracle plans to raise up to $50 billion for cloud buildout

source
target: 50 billion USD by 2026-12-31 00:00:00stated

Raise capex forecast to around $50 billion for AI data centers

source
target: 50 billion USD stated

Oracle Cloud Infrastructure revenue growth

source
target: 4.1 billion USD (68% climb) stated

Build AI data centers

source
target: 50 billion USD capex stated

Oracle launched AI-driven supply chain tools to predict disruptions and optimize inventory levels

source
by 2025-01-01 00:00:00stated

Oracle targets continued cloud acceleration and data center capacity expansion in FY2026

source
stated

Capital spending on AI infrastructure

source
target: 500+ billion USD by 2026-01-01 00:00:00stated

Accelerate revenue and profit growth through AI infrastructure capital expenditure

source
stated

Spend on CapEx right before it starts generating revenue

source
stated

Increased guidance for 2027 revenues by $4 billion

source
target: 4 billion USD increase by 2027-01-01 00:00:00stated

Relationship graph · 779 connections

Competes with
136
Developed by
107
Covered by
97
Customer of
75
Supplies to
68
Employs
38
located in
27
headquartered in
23
partnership cancelled
OpenAI →
Partnered with
OpenAI →
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com